ResMed (RMD) Given News Impact Score of 0.19

News coverage about ResMed (NYSE:RMD) has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ResMed earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.0130642209863 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

RMD has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note on Thursday. Northland Securities reiterated a “sell” rating and set a $55.00 price target on shares of ResMed in a research note on Friday, October 27th. Barclays lifted their price target on shares of ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a research note on Monday, September 25th. BMO Capital Markets lifted their price target on shares of ResMed to $82.00 and gave the stock a “market perform” rating in a research note on Tuesday, December 12th. Finally, Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a research note on Friday, October 27th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $70.57.

Shares of ResMed (NYSE:RMD) traded up $0.74 during trading hours on Friday, hitting $87.78. 339,181 shares of the stock traded hands, compared to its average volume of 463,300. ResMed has a 52 week low of $62.64 and a 52 week high of $88.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86. The firm has a market cap of $12,450.00, a P/E ratio of 35.54, a PEG ratio of 1.92 and a beta of 0.78.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million for the quarter, compared to the consensus estimate of $506.08 million. During the same quarter in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. equities research analysts predict that ResMed will post 3.04 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th were paid a $0.35 dividend. The ex-dividend date was Wednesday, November 8th. This represents a $1.40 annualized dividend and a dividend yield of 1.59%. ResMed’s dividend payout ratio is presently 56.68%.

In other news, CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $84.50, for a total value of $105,625.00. Following the sale, the chief financial officer now owns 71,772 shares in the company, valued at approximately $6,064,734. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Pendarvis sold 6,364 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $82.20, for a total transaction of $523,120.80. The disclosure for this sale can be found here. Insiders sold a total of 158,929 shares of company stock worth $13,181,009 in the last 90 days. 1.77% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.thestockobserver.com/2018/01/12/resmed-rmd-given-news-impact-score-of-0-19.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply